Compare Abeona Therapeutics Inc (ABEO) vs Conagra Brands Inc (CAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Conagra Brands Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Conagra Brands Inc trades at $14.93 (market cap $7.07B). The key difference: Conagra Brands Inc is far larger — about 16.7× Abeona Therapeutics Inc's market cap, and Conagra Brands Inc pays a 8.29% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CAG | |
|---|---|---|
Market Cap | $424.33M | $7.07B |
Sector | Health | Consumer Staples |
52-Week High | $7.45 | $20.02 |
52-Week Low | $4.17 | $12.58 |
Enterprise Value | $279.23M | $14.12B |
Dividend Yield | — | 8.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Conagra Brands (CAG) trades at $15.11, up 1.75% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported strong 2025 results with $11.6B revenue and $1.15B net income, but faces challenges with negative margins projected for 2026. Recent developments include a 50% dividend cut to $0.18 and new leadership appointments under CEO John Brase, who recently purchased 35,000 shares.
The outlook remains cautious despite attractive valuation metrics (P/E 10.06, P/S 0.64). While analyst consensus leans Hold (62.5%), the stock trades above the $13.67 target. Key risks include persistent inflation pressure, declining sales, and margin compression. The dividend reduction provides financial flexibility but signals ongoing turnaround challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →
